Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8IYG6
UPID:
LRC56_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IYG6; Q8N3Q4
Background:
Leucine-rich repeat-containing protein 56 plays a crucial role in the assembly of dynein arms, essential components for ciliary function. This protein's involvement in the intricate process of ciliary motility underscores its significance in cellular operations.
Therapeutic significance:
Given its pivotal role in primary ciliary dyskinesia, particularly Ciliary dyskinesia, primary, 39, understanding the function of Leucine-rich repeat-containing protein 56 could pave the way for innovative treatments. Targeting the underlying genetic variants offers a promising avenue for therapeutic intervention.